![](/img/cover-not-exists.png)
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
Verstovsek, Srdan, Odenike, Olatoyosi, Singer, Jack W., Granston, Tanya, Al-Fayoumi, Suliman, Deeg, H. JoachimVolume:
9
Language:
english
Journal:
Journal of Hematology & Oncology
DOI:
10.1186/s13045-016-0367-x
Date:
December, 2016
File:
PDF, 576 KB
english, 2016